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Hydroxychloroquine (HCQ), the hydroxyl derivative of
chloroquine (CQ), is widely used in the treatment of
rheumatological conditions (systemic lupus erythematosus,
rheumatoid arthritis) and is being studied for the treatment
and prevention of COVID-19. Here, we investigate through
mathematical modelling the safety profile of HCQ, CQ and other
QT-prolonging anti-infective agents to determine their risk
categories for Torsade de Pointes (TdP) arrhythmia. We performed
safety modelling with uncertainty quantification using a risk
classifier based on the qNet torsade metric score, a measure of the
net charge carried by major currents during the action potential
under inhibition of multiple ion channels by a compound.
Modelling results for HCQ at a maximum free therapeutic
plasma concentration (free Cmax) of approximately 1.2 µM
(malaria dosing) indicated it is most likely to be in the high-
intermediate-risk category for TdP, whereas CQ at a free Cmax of
approximately 0.7 µM was predicted to most likely lie in the
intermediate-risk category. Combining HCQ with the
royalsocietypublishing
2antibacterial moxifloxacin or the anti-malarial halofantrine (HAL) increased the degree of human
ventricular action potential duration prolongation at some or all concentrations investigated, and was
predicted to increase risk compared to HCQ alone. The combination of HCQ/HAL was predicted to
be the riskiest for the free Cmax values investigated, whereas azithromycin administered individually
was predicted to pose the lowest risk. Our simulation approach highlights that the torsadogenic
potentials of HCQ, CQ and other QT-prolonging anti-infectives used in COVID-19 prevention and
treatment increase with concentration and in combination with other QT-prolonging drugs..org/journal/rsos
R.Soc.Open
Sci.8:2102351. Introduction
The cinchona alkaloid quinine (QUIN), along with synthetically produced chloroquine (CQ), are
quinoline compounds which have been used in the treatment of malaria for decades. The more
soluble hydroxy derivative of CQ is hydroxychloroquine (HCQ). CQ and HCQ are diprotic bases
which accumulate in acid vesicles including lysosomes over time. Many of their multiple biological
activities including their antiviral action are associated with increased vesicle pH [1]. Both drugs have
been shown to block various cardiac ion channels [2].
HCQ was initially developed as an anti-malarial drug, sold as the sulfate salt under the trade name
Plaquenil [3]. HCQ is used for the treatment of a wide variety of conditions with the majority of use being
for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). For these indications, it is often
prescribed for use over months to years, and has had a good safety record including in pregnancy [1].
Early clinical studies reported few toxic side effects across HCQ anti-malarial treatment regimens [4].
Work in the late 1950s [5] explored the possibility of using 4-aminoquinolines in the treatment of
cardiac arrhythmias, although the specific action of reducing heart rate was not explored. Sumpter et al.
[6] showed evidence for risk of cardiomyopathy during long-term exposure to high doses of HCQ for
the treatment of patients with SLE and RA. The present treatment regime for SLE (generally 200–
400 mg d−1) [7] includes doses lower than the one originally used to treat arthritis or malaria [8].
Irreversible retinal toxicity is rare at current recommended doses [9,10]. Reported side effects have been
seen in greater than 1000mg d−1 dosage ranges [11–13]. The risk of retinopathy is increased with large
cumulative doses of HCQ (greater than 1000 g) [14]. The arrhythmogenic cardiotoxicity of the quinoline
and structurally related anti-malarial drugs are well documented [15]; in particular, effects on
hypotension and electrocardiographic QT interval prolongation have been reported. Capel et al. [16] in
2015 showed that HCQ also inhibits the pacemaking current If and offers the potential of being used as
a bradycardic agent. They also noted additional effects on the L-type calcium channels and delayed rectifier
potassium channels in isolated guinea pig sinoatrial node cells, indicating multi-ion channel block in
cardiac cells. With the increased re-purposing of CQ and HCQ [14], including for the treatment
(SOLIDARITY trial, ISRCTN83971151 and UK RECOVERY trial, ISRCTN50189673) and prevention of
COVID-19, there is a need to critically assess the cardiovascular safety profiles of these anti-malarials.
Since the advent of mathematical modelling of cardiac cell activity in the 1960s [17], major new
insights have emerged in the field, along with approaches to calibrating such models from
experimental data [18], and recognition of the need to quantify uncertainty in predictions [19].
Mathematical modelling has since been shown to be useful in elucidating the requirements for reliable
risk assessment predictions, such as the need to account for the actions of compounds on multiple ion
channels [20], and has helped to guide experimental design considerations for ion channel screening
experiments [21,22].
Prolongation of the QT interval on the surface electrocardiogram (ECG) is a surrogate measurement
of prolonged ventricular action potential duration (APD). Dispersion of repolarization (DR) is a result of
heterogeneous lengthening of APD throughout the ventricular myocardium, often across the ventricular
walls. This DR and the tendency of prolonged APD associated with early afterdepolarizations (EADs)
provide the substrate of polymorphic ventricular tachyarrhythmia (VT) associated with long QT
syndrome (LQTS) [23], Torsade de Pointes (TdP) VT [24]. The vast majority of acquired LQTS cases
(which are more prevalent than congenital LQTS cases) are the results of electrolyte abnormalities [25]
or adverse drug effects [26], the latter particularly due to interaction with the human Ether-à-go-go-
Related Gene (hERG), which encodes the pore-forming subunits (Kv11.1) of the channel carrying the
rapidly activating delayed rectifier current, IKr.
In drug development, hERG IC50 value estimates are used in the pre-clinical assessment of TdP risk.
Redfern et al. [27] proposed [hERG IC50/EFTPCmax] as an improvement over the simplified [hERG IC50].
royalsocietypublishing.org/journal/rsos
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3Mirams et al. [20] showed a simulated evaluation of multi-channel effects at the whole-cell level could be
used to improve this early prediction of TdP risk. The comprehensive in vitro proarrhythmia assay (CiPA)
initiative was later established as a novel cardiac safety screening paradigm that takes into account multi-
channel drug effects intended to replace the former regulatory strategy which relied on hERG block and
QT prolongation, sensitive predictors of TdP which lack specificity [28].
In patients with compromised organ function, such as in COVID-19, understanding drug safety and
drug interactions is critical. In this study, we use a computational approach, based on a classifier
developed by the CiPA initiative [29], to predict the clinical torsadogenic risk categories associated
with CQ, HCQ and other commonly used anti-infective agents known to prolong the QT interval. We
also use an independent block model to assess the safety profile of combination therapies and show
that torsadogenic potentials of HCQ, CQ and other QT-prolonging anti-infectives used in COVID-19
prevention and treatment increase with concentration and in combination with other QT-prolonging
drugs. Although the interest in CQ and HCQ for COVID-19 prophylaxis/treatment has waned, it is
hoped that our approach may be considered for the screening of potential future therapies/
combination therapies.c.Open
Sci.8:2102352. Methods
In 2015, we showed that HCQ inhibits If, L-type calcium channels, and slow and rapid delayed rectifier
potassium channels in isolated guinea pig sinoatrial node cells [16]. Five minutes of exposure to 3 µM
HCQ conveyed a statistically significant reduction in ICaL (12 ± 4% reduction in max. conductance, n =
6) and IKr (35 ± 4% reduction across step lengths rendering maximal current activation, n = 5) at p <
0.05, analysed using repeated-measures ANOVA. We used these data to approximate IC50s for the
actions of HCQ on IKr, ICaL and IKs by fitting the parameters of a Hill curve (assuming a Hill
coefficient of 1 [20]). HCQ blocked channels in the following order of potency: IKr > IKs > ICaL. IC50
values for other anti-infective compounds of interest including azithromycin (AZ), chloroquine (CQ),
halofantrine (HAL), lopinavir/ritonavir (LOP/RIT), moxifloxacin (MOX) and QUIN simulated in this
study were taken from the literature, and are shown in electronic supplementary material, table S1.
Based on the availability of ion channel block data for each compound, changes in up to seven ion
currents, namely IKr, IKs, IK1, ICaL, INa, INaL, Ito, were inputted into the CiPA version of the O’Hara-
Rudy (ORd) human ventricle mathematical action potential model [29]. For example, based on the
values presented in electronic supplementary material, table S1, AZ was assumed to block IKr, INaL,
IKs and Ito with IC50s of 70.8, 189.1, 470.0 and 88.8 µM, respectively. Drug block was modelled using
conductance block where a proportion bi of channel type i are blocked, and the maximal density of
the current is then scaled by ð1 biÞ [20]. For simulation of combinations of drugs, the Bliss model of
independent block was assumed [30], in which the total proportion of channels blocked arising from
the combination of the block by drugs 1 and 2 was given by
bi ¼ b1,i þ b2,i  b1,ib2,i: ð2:1Þ
That is, block occurs when one compound, the other, or both are bound to an individual channel, and
any of these scenarios leads to complete block of an individual channel. Combinations of drugs were
applied at plasma concentrations based on the ratio of free Cmax for drugs from clinical studies
referenced in electronic supplementary material, table S1 (where a range is shown, the highest
available Cmax was used). A torsade metric score was calculated for each compound, computed as the
average qNet at 1–4× Cmax [28]. Briefly, qNet is a measure of the net charge crossing the membrane
during a simulated action potential repolarization, calculated as the integral or area under the curve
of a net current, INet, defined as
INet ¼ ICaL þ INaL þ IKr þ IKs þ IK1 þ Ito: ð2:2Þ
A previous study found that estimates of pIC50 from repeated ion channel screens followed a logistic
form, i.e. pIC50∼ logistic(µ, σ) [21], where µ is the mean and σ is a spread parameter. Obtaining a value
for σ in each of the affected ion channels allows uncertainty in IC50 estimates to be propagated through to
APD and qNet predictions. We used previously reported values of σ [21] for IKr, IKs, INa, ICaL and Ito, or a
conservative value of 0.15 for ion channels for which this information was not available (INaL and IK1). A
pIC50 estimate for each channel of interest was subsequently sampled from the corresponding logistic
distribution—a process which was repeated 1000 times for each compound, resulting in 1000 distinct
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Figure 1. (a)(i) APD–concentration curves with 90% credible intervals from 1000 samples for control and azithromycin (AZ),
chloroquine (CQ), halofantrine (HAL), lopinavir/ritonavir (LOP/RIT), moxifloxacin (MOX) and quinine (QUIN), with selected APs at
concentrations of 1× free Cmax (ii) and 4× free Cmax (iii). Combinations of hydroxychloroquine (HCQ) with AZ, HAL and MOX





outputs allowed us to obtain an estimate of the 90% credible interval for simulated response curves. All
AP simulations and qNet calculations were performed using ApPredict, a bolt-on extension to Chaste
(which also has a web-portal front end [31]). All simulation data and codes required to run the
simulations are freely available in the Github repository: https://github.com/CardiacModelling/risk-
stratification-anti-malarials.3. Results
In this study, we used increases in the cellular APD as a surrogate for QT interval prolongation [20]. The
effects of each of the drugs on the APD were tested at log-spaced concentrations ranging from 0.001 to
100 µM and plotted in terms of the free Cmax, in order to measure the % change in APD90 with
concentration. The APD90 as a function of concentration is shown for AZ, CQ, HAL, LOP/RIT, MOX
and QUIN in figure 1a, with APs at concentrations equivalent to 1× and 4× free Cmax highlighted. The
compounds investigated generally had a free Cmax which is much less than the hERG IC50 and so
produced only a small degree of APD prolongation at 1× free Cmax, including lopinavir/ritonavir.
HAL on the other hand produced substantial APD prolongation at 1× free Cmax due to comparable
values of hERG IC50 and free Cmax. QUIN produced smaller but still substantial APD prolongation at
1–4× free Cmax. At a concentration 4× free Cmax, LOP/RIT and CQ also produced fairly substantial
APD prolongations, whereas this remained comparatively small for AZ and MOX.
Figure 1b–d shows APD-concentration curves for HCQ and various drugs administered alone, and in
combination with HCQ. While the antibiotics AZ and MOX both had very minor APD prolonging effects
when administered alone, they were both predicted to increase the overall degree of APD prolongation
slightly when given with HCQ compared to HCQ alone. Both HAL and HCQ had a considerable effect
when administered individually, so produced a substantial APD prolongation when combined
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Figure 2. qNet–concentration curves with 90% credible intervals from 1000 samples for (a) azithromycin (AZ), chloroquine (CQ),
halofantrine (HAL), lopinavir/ritonavir (LOP/RIT), moxifloxacin (MOX) and quinine (QUIN), and (b) hydroxychloroquine (HCQ), HCQ/AZ,
HCQ/HAL and HCQ/MOX. (c) Torsade metric scores for individual compounds and combinations, separated into low, intermediate and





Figure 2 shows the concentration-qNet curves for individual compounds and drug combinations, as
well as associated torsade metric scores. Based on APD prolongation at a concentration of 1–4× free Cmax
in figure 1, one would expect lopinavir/ritonavir to be slightly riskier than CQ. The qNet for CQ at this
concentration, however, was lower (riskier) than for lopinavir/ritonavir (figure 2a), highlighting the
different information provided by qNet; namely, that the balance of currents leading to APD
prolongation is altered in a riskier way for CQ.
AZ was predicted to have the safest (highest) median qNet, yet the uncertainties around lopinavir/
ritonavir and QUIN were greater, so they could be the safer compounds/combination. Lopinavir and
ritonavir have almost identical hERG IC50s, which also coincide somewhat with the ICaL and INaL
IC50s for ritonavir, all of which would be expected to influence the degree of APD prolongation in the
model. Therefore, as the concentration approaches the hERG (and other) IC50 values there were
several inputs close to the region of maximum uncertainty in the dose-response curve, generating
large uncertainty in the output.
Combinations of drugs with HCQ decreased qNet in the order HAL >MOX>AZ (figure 2b). The
torsade metric scores shown in figure 2c reveal that HCQ/HAL was predicted to be the riskiest
combination of drugs, whereas HAL was predicted to be a highly risky individual drug. At the other
end of the scale, AZ was the only compound placed in the low-risk category. However, combining
AZ with HCQ resulted in a most likely high-risk outcome. CQ was placed in the intermediate-high-
risk category, compared to mostly high risk for HCQ. As a free Cmax for HCQ treatment for which
plasma binding was taken into account was not available for SLE and/or COVID doses, we used a
value associated with a malaria dose [32].4. Discussion
In this study, we used a previously developed classifier [29] to predict the clinical torsadogenic risk
category associated with commonly used anti-malarials and anti-infective agents which prolong the




6therapies that block multiple ion channels. These simulations were based on the earliest pre-clinical data
available (measurement of IC50s, typically from high-throughput assays), and integrate multi-channel
effects to better predict risk classifications of drugs. Drugs such as CQ and HCQ have garnered a lot
of attention over many years as they appear to work via multiple mechanisms and hence have shown
promise in several disease conditions. Most recently, significant interest in the compounds was shown
regarding the treatment and prevention of COVID-19. This interest has waned after cessation of the
HCQ arm of the RECOVERY trial [33] and lack of impact, combined with the potential for adverse
events [34,35], although support for the use of HCQ, AZ and their combined use continues to appear
in recent publications in both the peer-reviewed [36,37] and popular literature [38] and discussions
continue as to the merits of adjuvant therapy with zinc supplementation [39,40].
Drug safety requires the ability to predict and assess risk with an acceptable level of certainty
including on major target organs [41]. We have taken advantage of recent developments in
computational modelling [21,29] and knowledge derived from single-cell electrophysiological
measurements of different quinolines (including CQ, HCQ, quinidine, QUIN and HAL) on up to
seven major ion currents including IKr and ICaL to stratify the risk of some of these compounds both
individually and in combination with other compounds. Furthermore, as such models require
increased scrutiny for use in safety-critical applications [19], we have performed uncertainty
quantification. Our modelling showed that combining HCQ with AZ prolonged APD to a greater
extent than the use of either individually (albeit this was notable only at 4× free Cmax), and placed
this combination in the high-risk category associated with measurable/unacceptable incidence of TdP.
Furthermore, combining HCQ with MOX or HAL was also predicted to increase TdP risk.
Data in animal models have previously shown HCQ to have multi-channel actions including on
calcium and potassium currents [16]. It is known that concurrent block of calcium currents with IKr
inhibition can protect against TdP and our modelling data suggest this is indeed the case for many
compounds, including HCQ at low concentrations. Modelling results for a free Cmax of approximately
1.2 µM indicated that the balance of potassium and calcium current inhibitions observed would not
be expected to lengthen the human ventricular action potential significantly at a dose of 1× free Cmax
(figure 1), but did so at 4× free Cmax, which resulted in an overall high-intermediate-risk category for
HCQ. However, we also showed that accounting for variability in our experimental data led to a
range of possibilities. With the exception of HAL and HCQ/HAL, all compounds and combinations
investigated produced credible intervals for the torsade metric score that spanned at least two risk
categories. Gathering more high-quality experimental data regarding the multi-channel inhibition
effects of HCQ and other anti-malarials would allow us to predict with more confidence the most
plausible APD prolongation range and risk category. We could also have accounted for different Hill
coefficients, although it has been noted previously that the associated level of variability in their
measurement is so high that it is unclear whether including the Hill coefficient from ion channel
screening adds useful information [21]. It should be noted, in addition, that the IC50 used as a model
input has limitations as a measure of drug block, in that its value may depend on the
electrophysiology protocol used [42,43], and, relatedly, it is unable to account for dynamic, state-
dependent effects of a compound. Recent studies have integrated dynamic effects into computational
models through the use of drug-binding kinetic schemes with rates inferred from specialized
electrophysiology protocols [29] and atomistic scale measurements [44].
Our modelling predicted that CQ at a free Cmax of approximately 0.7 µM was generally safer than
HCQ at a free Cmax of approximately 1.2 µM (used in the treatment of malaria at 400 mg [32];
figure 2). However, it should be noted that the free Cmax for HCQ is approximately 2 times greater
than that for CQ; if the same free Cmax is used for both compounds then the risk scores are
comparable (electronic supplementary material, figure S1). High doses of CQ are thus still expected to
pose a high risk. Furthermore, the free Cmax we used for HCQ was for a malaria dose, which is a
higher dose than for SLE. We expect that HCQ at the lower doses used for SLE thus remains
generally safe (towards the intermediate-risk category), whereas higher doses used for COVID-19 will
place HCQ unequivocally in the high-risk category (electronic supplementary material, figure S1). This
is in keeping with clinical experience where CQ and HCQ are known to cause sudden death in
overdose but have an otherwise good safety record in the treatment of malaria and SLE, respectively [15].
The risk categories presented in this study are based on a combination of adverse events, case reports
and clinical judgement by an expert panel, more information about which can be found on the CiPA
website [45]. The categories should not be interpreted as the risk of developing TdP when taking a
particular compound (which would suggest that someone taking HCQ is at high risk of developing




7rare) can be attributed to a particular compound. To put some of the risk categories in context, they are
compared to quinidine (which has known TdP risk) in electronic supplementary material, figure S2. The
torsade metric score (correctly) identified quinidine as high risk, suggesting that it is highly probable
that TdP can be attributed to quinidine in cases where it arises in patients (far more so than for other
compounds tested), which is consistent with clinical experience and the known safety profile of quinidine.
A comparison of the results in this study with risk scores/categories from previous classifiers and
databases (where available) is shown in electronic supplementary material, table S2. While it is hard
to compare directly these scores, it can be seen that there is reasonable agreement across the different
classification systems regarding which drugs are risky, such as quinidine and HAL, and which drugs
pose less of a TdP risk, such as QUIN. This suggests that the qNet metric may capture to a reasonable
degree relative differences between compounds in the cellular-level mechanisms that determine TdP.
Nonetheless, some discrepancies are apparent. One reason for this is that our model predictions are
highly sensitive to the free Cmax input. This is not ideal as effective free therapeutic plasma
concentrations are not easily obtained from the literature. A final crucial point regarding the classifier
is that risk category prediction does not necessarily rely on accurate prediction of APD prolongation
[20] and indeed it has been tested for predictions without considering APD [28]; as such, here we use
the same classifier to assess cardiac risk while making no claims about the accuracy of the degree of
APD prolongation in the model. Further, while we have searched the literature for ion channel
blocking effects of the listed compounds, we acknowledge that many compounds have active
metabolites and that any potential impact of these upon APD has not been modelled in this analysis.
Patient risk factors can also predispose to cardiotoxicity, some of which may be more common in
COVID-19, e.g. electrolyte imbalances, renal failure, drug interactions. COVID-19 also appears to affect
the heart (e.g. myocarditis), which may additionally increase cardiotoxicity risk [46]. COVID-19 is also
associated with acute kidney injury and electrolyte abnormalities [47]. Safety of drug–drug
interactions (including combinations of anti-malarials) are an important consideration when being
explored as a therapeutic in comorbid patients [48].5. Conclusion
The safety profile of both CQ and HCQ are well-established. Since the SARS-CoV-2 outbreak, the ability
of CQ/HCQ to inhibit certain coronaviruses has been explored. Although interest in HCQ use for acutely
unwell COVID-19 patients has waned, there is a continued interest in potential use at symptom onset or
as a prophylactic, with combination therapies with zinc and/or AZ under continued discussion in peer-
reviewed and popular literature. In this study, we demonstrate an in silico safety assessment with
uncertainty quantification based on the CiPA qNet torsade metric score. At a free Cmax of
approximately 1.2 µM as seen in malaria treatment, HCQ would most likely be placed in the high-
intermediate-risk category for TdP arrhythmia, whereas CQ was predicted to most likely lie in the
intermediate-risk category at a free Cmax of approximately 0.7 µM. Combining HCQ with the
antibacterial MOX, or the anti-malarial HAL was predicted to increase risk compared to
administration of HCQ alone, increasing the degree of human ventricular APD prolongation at some
or all concentrations investigated. Further clinical work will be required in order to assess the cardiac
effects of HCQ at different doses as used in specific disease populations.
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Table S1: A summary of IC50s (µM) and effective free therapeutic plasma concentrations 
(free Cmax; µM) for different anti-malarial compounds using values from the literature. 










70.8 - - 189.1 470 88.8 - 0.4 – 
1.937 
CQ [1], [3], 
[4]  




0.38 1.9 331.2 - - - - 0.172 – 
0.57 
HCQ [6], [7] 5.62 26.9   9.33   1.22 
Lopinavir [1] 5.17 15.6 - - - - - 0.704 
Moxifloxacin 
[1], [2] 
93.0 - - 382.3 50.3 - - 3.5 – 
4.111 
Ritonavir [1] 5.16 8.23 - 7.18 - - - 0.437 




5.17 27.18 24.15 11.05 37.45 79.25 - 1.83 – 
3.9567 






















Azithromycin 4   KR  Low 
Chloroquine 3 2 4 KR  Intermediate 
Halofantrine 4  3 KR TdP+ High 
Hydroxychloroquine 4   KR  High 
Lopinavir/ritonavir    PR  Intermediate 
Moxifloxacin 4 3  KR TdP+ Intermediate 
Quinidine 1 1 1 KR TdP+ High 
Quinine 4 2  CR  Intermediate 
Abbreviations for Credible Meds are as follows: CR (conditional risk); KR (known risk); 
possible risk (PR). For the Harmer risk score, the numbers correspond to: (1) Class I anti-
arrhythmics; (2) QRS prolonging drugs; (3) Non-QRS prolonging drugs. The Mirams/Redfern 
categories correspond to: (1) Class Ia and III anti-arrhythmics; typically associated with a 
considerable, but acceptable, risk of TdP; (2) Drugs that have been withdrawn from the market 
due to unacceptable TdP risk; (3) Drugs with a measurable incidence of TdP, or for which 
numerous case reports exist; (4) Drugs for which there have been isolated case reports of TdP; 
(5) Drugs for which there have been no published reports of TdP. For the Kramer category, 






Figure S1: qNet-concentration curves with 90% credible intervals from 1000 samples for (A) 
chloroquine (CQ), at normal and high (2×) dose (relative to the default malaria dose used), 
and hydroxychloroquine (HCQ), and (C) HCQ at normal, low (0.5×), and high doses (2×) 
(relative to the default malaria dose used). Corresponding torsade metric scores for CQ (B) 
and HCQ (D), separated into low, intermediate, and high risk based on thresholds in [12]. 
 
 
Figure S2: Torsade metric scores for individual compounds and combinations, separated into 
low, intermediate, and high risk based on thresholds in [12], shown as red and green dotted 
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